NCT01028287View on ClinicalTrials.gov

Adrenocorticotropic Hormone (ACTH) Treatment of Nephrotic Range Proteinuria in Diabetic Nephropathy (NRDN)

PHASE4CompletedINTERVENTIONAL
Enrollment

15

Participants

Timeline

Start Date

May 31, 2009

Primary Completion Date

December 31, 2010

Study Completion Date

July 31, 2011

Conditions
Diabetic NephropathyNephrotic Syndrome
Interventions
DRUG

ACTH

Patients with nephrotic range proteinuria randomized to this group will receive 16 units ACTHargel sub-cutaneously every day.

DRUG

ACTH

Patients with nephrotic range proteinuria randomized to this group will receive 32 units ACTHargel sub-cutaneously every day.

Trial Locations (1)

37404

Southeast Renal Research Institute, Chattanooga

Sponsors

Collaborators (1)

Mallinckrodt
All Listed Sponsors
collaborator

Mallinckrodt

INDUSTRY

lead

Southeast Renal Research Institute

OTHER